132 related articles for article (PubMed ID: 15040868)
1. Clinical trials of atrasentan in hormone-refractory prostate cancer.
Lee D
Clin Prostate Cancer; 2003 Sep; 2(2):84-6. PubMed ID: 15040868
[No Abstract] [Full Text] [Related]
2. Atrasentan for metastatic hormone refractory prostate cancer.
Murphy G
Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
[TBL] [Abstract][Full Text] [Related]
3. The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer.
Fisher M
Clin Prostate Cancer; 2002 Sep; 1(2):79-80. PubMed ID: 15046697
[No Abstract] [Full Text] [Related]
4. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
[TBL] [Abstract][Full Text] [Related]
5. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
Nelson JB; Love W; Chin JL; Saad F; Schulman CC; Sleep DJ; Qian J; Steinberg J; Carducci M;
Cancer; 2008 Nov; 113(9):2478-87. PubMed ID: 18785254
[TBL] [Abstract][Full Text] [Related]
6. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Carducci MA; Saad F; Abrahamsson PA; Dearnaley DP; Schulman CC; North SA; Sleep DJ; Isaacson JD; Nelson JB;
Cancer; 2007 Nov; 110(9):1959-66. PubMed ID: 17886253
[TBL] [Abstract][Full Text] [Related]
7. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB; Nabulsi AA; Vogelzang NJ; Breul J; Zonnenberg BA; Daliani DD; Schulman CC; Carducci MA
J Urol; 2003 Mar; 169(3):1143-9. PubMed ID: 12576870
[TBL] [Abstract][Full Text] [Related]
8. Endothelin receptor antagonists.
Nelson JB
World J Urol; 2005 Feb; 23(1):19-27. PubMed ID: 15654644
[TBL] [Abstract][Full Text] [Related]
9. New drug slows prostate-cancer progression.
van der Boon J
Lancet Oncol; 2002 Apr; 3(4):201. PubMed ID: 12067675
[No Abstract] [Full Text] [Related]
10. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
Thakkar SG; Choueiri TK; Garcia JA
Curr Oncol Rep; 2006 Mar; 8(2):108-13. PubMed ID: 16507220
[TBL] [Abstract][Full Text] [Related]
11. Atrasentan: targeting the endothelin axis in prostate cancer.
Jimeno A; Carducci M
Expert Opin Investig Drugs; 2004 Dec; 13(12):1631-40. PubMed ID: 15566319
[TBL] [Abstract][Full Text] [Related]
12. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Carducci MA; Padley RJ; Breul J; Vogelzang NJ; Zonnenberg BA; Daliani DD; Schulman CC; Nabulsi AA; Humerickhouse RA; Weinberg MA; Schmitt JL; Nelson JB
J Clin Oncol; 2003 Feb; 21(4):679-89. PubMed ID: 12586806
[TBL] [Abstract][Full Text] [Related]
13. Atrasentan: a rationally designed targeted therapy for cancer.
Jimeno A; Carducci M
Drugs Today (Barc); 2006 May; 42(5):299-312. PubMed ID: 16801993
[TBL] [Abstract][Full Text] [Related]
14. New principles in the treatment of hormonal refractory prostate cancer.
Nisen P
Scand J Urol Nephrol Suppl; 2003; (212):20-2. PubMed ID: 12841323
[No Abstract] [Full Text] [Related]
15. Endothelin inhibition: novel therapy for prostate cancer.
Nelson JB
J Urol; 2003 Dec; 170(6 Pt 2):S65-7; discussion S67-8. PubMed ID: 14610413
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in prostate cancer--are we our own worst enemy?
Dawson NA
Cancer; 2008 Nov; 113(9):2376-8. PubMed ID: 18780314
[No Abstract] [Full Text] [Related]
17. Endothelin receptor antagonists in the treatment of prostate cancer.
Lassiter LK; Carducci MA
Semin Oncol; 2003 Oct; 30(5):678-88. PubMed ID: 14571415
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Michaelson MD; Kaufman DS; Kantoff P; Oh WK; Smith MR
Cancer; 2006 Aug; 107(3):530-5. PubMed ID: 16804927
[TBL] [Abstract][Full Text] [Related]
19. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.
Jimeno A; Carducci M
Expert Rev Anticancer Ther; 2005 Jun; 5(3):419-27. PubMed ID: 16001950
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Zonnenberg BA; Groenewegen G; Janus TJ; Leahy TW; Humerickhouse RA; Isaacson JD; Carr RA; Voest E
Clin Cancer Res; 2003 Aug; 9(8):2965-72. PubMed ID: 12912943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
